Get the Stockscreener App
1.11
5.13%
-0.06
After Hours:
1.13
0.02
+1.80%
Coherus Biosciences Inc Stock (CHRS) Latest News
CHRSCoherus BioSciences Secures Credit Financing with Pharmakon Advisors - br.ADVFN.com
BlackRock, Inc. Reduces Stake in Coherus BioSciences Inc - GuruFocus.com
Coherus BioSciences (NASDAQ:CHRS) Stock Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Coherus BioSciences’ (CHRS) Buy Rating Reiterated at HC Wainwright - Defense World
Coherus BioSciences's SWOT analysis: stock faces headwinds amid oncology pivot - MSN
Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright - MarketBeat
Positive Phase II trial results for Coherus' casdozokitug - The Pharma Letter
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 - The Manila Times
Coherus Presents Final Phase 2 Clinical Casdozokitug - GlobeNewswire
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with ... - The Bakersfield Californian
CHRS (Coherus BioSciences) Market Cap : $160.1 Mil (As of Jan. 21, 2025) - GuruFocus.com
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Coherus BioSciences (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise - Simply Wall St
Coherus to Present Final Phase 2 Casdozokitug Combination - GlobeNewswire
Coherus BioSciences to Present Groundbreaking Cancer Treatment Data at ASCO-GI 2025 - StockTitan
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development - Seeking Alpha
Short Interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) Drops By 7.0% - MarketBeat
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition - Investing.com
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Coherus BioSciences to divest UDENYCA franchise for up to $558.4M - MSN
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Disciplined Growth Investors Inc. MN - MarketBeat
California-Based Biotech Rallies Strongly Following $558.4M Divestiture - MSN
Coherus price target raised at Baird on agreement to sell Udenyca - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board By Investing.com - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board - Investing.com
Intas acquires Udenyca from Coherus BioSciences in potential $558 million deal - BioProcess Insider
Coherus BioSciences (FRA:8C5) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
CHRS (Coherus BioSciences) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Coherus Biosciences Announces Board Member Resignation - TipRanks
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition By Investing.com - Investing.com Australia
Latham Watkins Advises Coherus in Divesture of UDENYCA Franchise to Intas Pharmaceuticals - Latham & Watkins LLP
Accord acquires Coherus’ Udenyca business - The Pharma Letter
Intas to acquire Coherus’ Udenyca assets for up to $558m - World Pharmaceutical Frontiers
Goodbye Biosimilars: Coherus Sells Udenyca To Intas For Half A Billion - News & Insights
S&P 500 Total Return (TCM23) Quote - The Globe and Mail
Intas Pharma to acquire Udenyca business from Coherus BioSciences - Medical Dialogues
Coherus Continues Funding IO Ambitions By Offloading Biosimilars - News & Insights
TSX Consumer Discretionary Capped Index (TTCD) QuotePress Release - The Globe and Mail
TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail
Redwood City-based Coherus' stock surges after major drug sale - The Business Journals
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Raleigh pharmaceutical company expands portfolio with $558M deal - The Business Journals
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M - BioPharma Dive
Coherus unloads Udenyca in $558M deal to power immuno-oncology ambitions - FirstWord Pharma
Coherus shares surge on $558M Udenyca divestiture deal By Investing.com - Investing.com South Africa
Coherus shares surge on $558M Udenyca divestiture deal - Investing.com
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):